232 related articles for article (PubMed ID: 34920174)
1. In vitro activity of cefiderocol against Gram-negative bacterial pathogens in Germany.
Thelen P; Henriksen AS; Longshaw C; Yamano Y; Caldwell B; Hamprecht A
J Glob Antimicrob Resist; 2022 Mar; 28():12-17. PubMed ID: 34920174
[TBL] [Abstract][Full Text] [Related]
2. Activity of ceftolozane-tazobactam, ceftazidime-avibactam, meropenem-vaborbactam, cefiderocol and comparators against Gram-negative organisms causing bloodstream infections in Northern Italy (2019-2021): emergence of complex resistance phenotypes.
Bianco G; Boattini M; Comini S; Iannaccone M; Casale R; Allizond V; Barbui AM; Banche G; Cavallo R; Costa C
J Chemother; 2022 Sep; 34(5):302-310. PubMed ID: 35098907
[TBL] [Abstract][Full Text] [Related]
3.
Shortridge D; Streit JM; Mendes R; Castanheira M
Microbiol Spectr; 2022 Apr; 10(2):e0271221. PubMed ID: 35262394
[TBL] [Abstract][Full Text] [Related]
4. [In Vitro Activity of Ceftazidime-avibactam and Colistin Against Carbapenem-Resistant Klebsiella pneumoniae Clinical Isolates].
Hoşbul T; Aydoğan CN; Kaya S; Bedir O; Gümral R; Albay A
Mikrobiyol Bul; 2022 Apr; 56(2):218-229. PubMed ID: 35477226
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of the newly approved antimicrobial agent Cefiderocol against Carbapenem resistant Gram negative clinical isolates.
Khanchandani H; Chaudhury M; Rao MS; Ramakrishna N; Venkataramana B; Chaudhury A
Indian J Med Microbiol; 2024; 48():100556. PubMed ID: 38447857
[TBL] [Abstract][Full Text] [Related]
6. Reduce susceptibility to cefiderocol in gram negative bacteria in children: Is hope already lost before it's even arrived?
Russo C; Mesini A; Mariani M; Tavella E; Sette C; Ugolotti E; Bartalucci C; Palmero C; Bandettini R; Castagnola E
J Infect Public Health; 2024 Apr; 17(4):624-631. PubMed ID: 38422857
[TBL] [Abstract][Full Text] [Related]
7. In vitro Activity of Cefiderocol and Ceftazidime-Avibactam, Against Carbapenemase-Producing Enterobacterales.
Ozyurt OK; Tufanoglu P; Cetinkaya O; Ozhak B; Yazisiz H; Ongut G; Turhan O; Ogunc D
Clin Lab; 2023 Jan; 69(1):. PubMed ID: 36649528
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and
Cruz-López F; Martínez-Meléndez A; Morfin-Otero R; Rodriguez-Noriega E; Maldonado-Garza HJ; Garza-González E
Front Cell Infect Microbiol; 2022; 12():884365. PubMed ID: 35669117
[TBL] [Abstract][Full Text] [Related]
9. In vitro antibacterial activity of cefiderocol against recent multidrug-resistant carbapenem-nonsusceptible Enterobacterales isolates.
Zhang Q; Neidig N; Chu TY; Divoky C; Carpenter J; Lee-Hsiao C; Threatt H; Sultana R; Bush K
Diagn Microbiol Infect Dis; 2022 May; 103(1):115651. PubMed ID: 35228130
[TBL] [Abstract][Full Text] [Related]
10.
Takemura M; Nakamura R; Ota M; Nakai R; Sahm DF; Hackel MA; Yamano Y
Antimicrob Agents Chemother; 2023 Dec; 67(12):e0034623. PubMed ID: 37971240
[No Abstract] [Full Text] [Related]
11. Evaluation of the inoculum effect of new antibiotics against carbapenem-resistant enterobacterales.
Danjean M; Hobson CA; Gits-Muselli M; Courroux C; Monjault A; Bonacorsi S; Birgy A
Clin Microbiol Infect; 2022 Nov; 28(11):1503.e1-1503.e3. PubMed ID: 35777602
[TBL] [Abstract][Full Text] [Related]
12. Activity of ceftolozane/tazobactam against Gram-negative isolates among different infections in Hong Kong: SMART 2017-2019.
Karlowsky JA; Lob SH; Khan A; Chen WT; Woo PCY; Seto WH; Ip M; Leung S; Wong QW; Chau RWY; DeRyke CA; Young K; Motyl MR; Sahm DF
J Med Microbiol; 2022 Apr; 71(4):. PubMed ID: 35451945
[No Abstract] [Full Text] [Related]
13. In vitro antibacterial activities of cefiderocol against Gram-negative clinical strains isolated from China in 2020.
Kohira N; Hackel MA; Oota M; Takemura M; Hu F; Mizuno H; Sahm DF; Yamano Y
J Glob Antimicrob Resist; 2023 Mar; 32():181-186. PubMed ID: 36513320
[TBL] [Abstract][Full Text] [Related]
14.
Borde K; Kareem MA; Sharma RM; Dass SM; Ravi V; Mathai D
Microbiol Spectr; 2023 Sep; 11(5):e0084723. PubMed ID: 37737637
[TBL] [Abstract][Full Text] [Related]
15. Global prevalence of cefiderocol non-susceptibility in Enterobacterales, Pseudomonas aeruginosa, Acinetobacter baumannii, and Stenotrophomonas maltophilia: a systematic review and meta-analysis.
Karakonstantis S; Rousaki M; Vassilopoulou L; Kritsotakis EI
Clin Microbiol Infect; 2024 Feb; 30(2):178-188. PubMed ID: 37666449
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of cefiderocol and other newly approved antimicrobials against multi-drug resistant Gram-negative pathogens recovered in intensive care units in Spain and Portugal.
Gijón D; García-Castillo J; Fernández-López MC; Bou G; Siller M; Calvo-Montes J; Pitart C; Vila J; Torno N; Gimeno C; Cruz H; Ramos H; Mulet X; Oliver A; Ruiz-Garbajosa P; Canton R
Rev Esp Quimioter; 2024 Feb; 37(1):69-77. PubMed ID: 37882320
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity of cefiderocol against clinically important carbapenem non-susceptible Gram-negative bacteria from Saudi Arabia.
Alzayer M; Alghoribi MF; Alalwan B; Alreheli A; Aljohani S; Bosaeed M; Doumith M
J Glob Antimicrob Resist; 2023 Mar; 32():176-180. PubMed ID: 36481491
[TBL] [Abstract][Full Text] [Related]
18. Ceftolozane/Tazobactam Activity Against Drug-Resistant
Pfaller M; Shortridge D; Chen WT; Sader H; Castanheira M
Infect Drug Resist; 2022; 15():6739-6753. PubMed ID: 36444213
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of ceftazidime-avibactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa collected in Malaysia: Results from the ATLAS Programme, 2013 to 2019.
Tuan Soh TS; Salvinder S; Chen VSY
Med J Malaysia; 2022 Mar; 77(2):174-184. PubMed ID: 35338624
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of antibiotics potentially effective against difficult-to-treat strains of Gram-negative rods: retrospective study.
Kroneislová G; Závora J; Adámková VG; Rýdlová A; Adámková V
Sci Rep; 2024 Apr; 14(1):8310. PubMed ID: 38594467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
